CSI Market
Sign In | Register

Dicerna Pharmaceuticals Inc (DRNA) Quarterly Cash Flow Statement

Quarterly · GAAP · USD millions
Access DRNA Annual Cash Flow →
Reviewing cash flow data across recent quarters allows users to assess how Dicerna Pharmaceuticals Inc adapts its cash strategy across cycles.
View historic periods: Download as CSV:
Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.
Quarterly Report, GAAP in USD millions
ITEM 		(Sep 30 2021)
9 Months 		(Jun 30 2021) (Mar 31 2021) (Dec 31 2020) (Sep 30 2020)
Operating Activities
Income-87.85
Depreciation & amortization3.94
Amortization of Other Assets0.00
Increase (Decrease) in Deferred Revenue179.63
Restructuring & Impairment Charges0.00
Provision For Loan Losses Expensed0.00
Inventories Decrease /-Increase0.00
R & D, Environmental and Other Expense0.00
Gain (Loss) on Disposition of Property Plant Equipment0.00
Share-based Compensation37.27
Income (Loss) from Equity Method Investments0.00
Financial Instruments and Foreign Currency Transaction0.00
Increase Decrease Research And License Receivable-
Non Cash Litigation Expense-
Increase Decrease In Litigation Settlement Payable-
Operating Lease Expense8.75
Noncash Litigation Expense-
Increase Decrease In Lease Liabilities-6.47
Change In Fair Value Of Derivative Liability-2.00
Increase Decrease In Contract With Customer Liability-103.86
Income taxes0.08
Losses/ -gains on Investments net0.00
Accounts Receivable36.30
Increase (Decrease) in Accounts Payable0.42
Accrued Expense0.00
Increase (Decrease) in Security Deposits0.00
Increase (Decrease) in Prepaid Expense and Other Assets-1.43
Other Working Capital0.00
Other Noncash Income (Expense)0.00
Other net0.00
Payments for (Proceeds from) Other Operating Activities3.58
Discontinued operations0.00
Net Cash flow from Operating Activities68.35
Investing Activities
Capital Expenditures-8.24
Sale of Capital Items0.00
Proceeds from Sale and Maturity of Held-to-maturity Securities451.47
Payments to Acquire Held-to-maturity Securities-493.07
Real Estate Investments0.00
Changes In Assets Held In Restriction-
Increase (Decrease) in Restricted Cash and Investments0.00
Payments for (Proceeds from) Loans0.00
Payments for (Proceeds from) Deposits0.00
Payments for (Proceeds from) Other Investments0.00
Payments for (Proceeds from) Federal Reserve and FHLB0.00
Acquisition Net of Cash Acquired0.00
Interest in Subsidiaries and Affiliates0.00
Sale of businesses0.00
Accounts payable0.00
Receivables0.00
Payments for (Proceeds from) Other Investing Activities0.00
Other Net0.00
Discontinued operations0.00
Net Cash Flow from Investing Activities-49.84
Financing Activities
Short-term debt Net0.00
Other borrowing transactions0.00
Long-term debt - borrowings0.00
Long-term debt - repayments0.00
Federal Home Loan Bank and Federal Funds0.00
Issuances / -repurchases of Comm. Stock22.51
Partnership and Parent Transactions0.00
Issuances / -repurchases of Pref. Stock0.00
Deposits, Annuities, Contract Holders Funds0.00
Other financing activities net0.00
Other net-149.84
Payments For Redeemable Convertible Preferred Stock Issuance Costs-
Preferred Stock Dividends And Other Adjustments-
Payments Of Redeemable Convertible Preferred Stock Issuance Costs-
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents132.39
Right Of Use Asset Obtained In Exchange For Operating Lease Liability15.30
Capital Expenditures Incurred But Not Yet Paid0.11
Payments Of Stock Issuance Costs Excluding Brokerage Commissions-
Payments of Dividends, Preferred Stock and Preference Stock0.00
Dividends paid0.00
Net Cash Flow from Financing Activities20.48
Effect of exchange rate on cash flow0.00
Discontinued operations0.00
Free Cash Flow60.11
Total Cash Flow38.99
4 historic quarters locked

Sign in to unlock the full Dicerna Pharmaceuticals Inc cash flow history.

Sign In Create Free Account

About DRNA Quarterly Cash Flow Statement

What this statement shows

This page presents issuer-reported cash flow data, including operating, investing, financing, net, and free cash flow, as disclosed in SEC 10-Q filings and normalized by CSIMarket.

Source & verification

  • Form: 10-Q
  • Filed with the SEC: n/a

Last updated

  • Page updated:
  • Data lineage: SEC filings - XBRL extraction - normalization in the CSIMarket.com database.

Figures are derived from filed reports and may be restated. Historical data is subject to revision.